Eli Lilly evaluated its investigational medicine against Novo Nordisk's Ozempic over an 80-week trial period in individuals with diabetes. Patients receiving the highest dose of retatrutide experienced an A1c blood sugar decrease of 2.2 percentage points, compared to 1.8 percentage points for the Ozempic group. The trial also tracked body weight, showing retatrutide achieved an average loss of 20.9% versus 9.4% for Ozempic. These comparative results specifically reflect participants who remained on their assigned treatment throughout the entire study.
Key points
Eli Lilly's investigational medicine outperformed Novo Nordisk's Ozempic in both blood su…: Eli Lilly's investigational medicine outperformed Novo Nordisk's Ozempic in both blood sugar control and weight reduction.
Patients who remained on the highest dose of retatrutide achieved more than double the pe…: Patients who remained on the highest dose of retatrutide achieved more than double the percentage of weight loss seen with Ozempic.
The reported outcomes reflect a targeted analysis of study participants who stayed on the…: The reported outcomes reflect a targeted analysis of study participants who stayed on their assigned therapy for the full trial duration.
Sources checked by our analysis pipeline: 1
Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine.
In the head-to-head study, people on the highest dose of Lilly’s drug, called retatrutide, saw a 2.2 percentage-point reduction in a measure of blood sugar called A1c after 80 weeks, while those on Ozempic saw a 1.8 percentage-point reduction.
Those on the highest dose of retatrutide also lost 20.9% of their weight, a highly significant amount considering that people with diabetes don’t tend to lose much weight on drugs. Meanwhile, those taking Ozempic lost 9.4% of their weight. These results are based on analyses looking only at the participants who stayed on treatment, not all participants.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Emergency responders are frantically searching through heavily damaged carriages in central Spain after a catastrophic collision involving a stationary rail vehicle. The
Neeraj Yadav, a three-time Asian Para Games gold medallist and prominent figure in the Indian para-athletics community, was found dead in Delhi on Tuesday night. Preliminary reports and statements from chief coach S Satyanarayana indicated he died by suicide, and his body was taken to Guru Teg Bahadur (GTB) Hospital for a postmortem examination as police investigate the circumstances. The unexpected loss has left fellow athletes and coaches in deep shock, remembering him as a vibrant, supportive mentor and a close…
A catastrophic rear-end collision between two passenger transports in central Spain has claimed at least ten lives and left numerous others hospitalized. Emergency responders and military units are actively searching through heavily damaged carriages for survivors while transport officials work to understand how both vehicles occupied the same track. This disaster immediately intensifies national scrutiny regarding railway safety protocols following an even deadlier rail tragedy earlier this year.